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Background: The optimal revascularization strategy for left main (LM) disease in the
era of drug-eluting stents has become controversial. Consensus guidelines recommend
coronary artery bypass graft surgery for the treatment of significant de novo LM
stenosis; however, the recommendation for unprotected left main coronary artery
(ULMCA) percutaneous coronary intervention has recently received a Class IIb
indication. This analysis will focus on outcomes of LM patients (pts) in the SYNTAX
trial at 4 years.
Methods: SYNTAX randomized pts with de novo 3 vessel (3VD) and/or LM disease
to PCI with TAXUS Express stents or CABG if suitable for equivalent
revascularization using either treatment. Analysis of this unprotected LM cohort was
prespecified and sufficiently powered.
Results: Three-year MACCE and the composite of death/stroke/MI were similar in
ULMCA- PCI and CABG-treated pts (Table). Stroke was significantly increased in
the CABG group and repeat revascularization was increased in the PCI arm at 3 years
(Table). MACCE was similar between groups in pts with lower SYNTAX Scores (0-
32: 23.2% vs 20.5%, p=0.45) but significantly increased in PCI pts with high scores
(≥33: 21.2% vs 37.3%, p=0.003).
Conclusion: At 3-years, no difference in MACCE was found between groups. There
was an advantage of PCI in stroke; a benefit in the need for reintervention was still
found in CABG. SYNTAX and other recent studies of LM disease suggest that in some
pts, PCI using drug-eluting stents may be as effective but less invasive than CABG.
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Background: The Nile PAX® dedicated drug-eluting stent (Minvasys SAS, France)
is a novel technology designed for percutaneous treatment of coronary bifurcation
lesions with a provisional approach that incorporates: 1. a cobalt-chromium alloy
designed to optimize scaffold of the bifurcation carina with maintenance of side branch
(SB) access without need for rewiring (Nile CroCo® platform, Minvasys SAS, France);
2. a non-polymeric coating (PAX) technology; and 3. a potent antiproliferative agent
(paclitaxel).
Methods: From Dec/08 to Mar/09, a total of 101 pts with single bifurcation lesion
were prospectively enrolled in this non-randomized, multicenter (10 sites in
Europe/South America) study. Lesion criteria were vessel size 2.5-3.5mm in the parent
vessel (PV) and 2.0-3.0mm in the SB, and lesion length <14mm in the PV.
Results: LAD/Dg was the most prevalent location (75%), and 60% had significant
involvement of both branches. In the procedure, PV was predilated in 97%; the study
stent was successfully attempted and implanted in 99%. Overall, 25% of SB received
an additional stent; and 94% of lesions had final kissing-balloon inflation.
Angiographic success (residual stenosis <50%, final TIMI 3 flow, and absence of
dissection) was achieved in 98%. There was only 1 major adverse cardiac event during
hospitalization, which was adjudicated as a non-Q myocardial infarction during
hospitalization, and no additional adverse events were reported up to 30 days. At 9
months, binary restenosis (primary endpoint) was 13.8% in the PV and 12.6% in the
SB, and clinical outcomes included 8.4% clinically-driven target lesion
revascularization (TLR) and no occurence of death or stent thrombosis.
Conclusion: The novel Nile PAX dedicated bifurcation polymer-free technology
demonstrated excellent performance in the treatment of complex bifurcation lesions,
including high procedural success and no events from discharge to 30 days FU. Up to
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Background: The clopidogrel-statin interaction has not been examined using time-
varying drug exposure ascertainment. We examined whether statin use modified the
association between clopidogrel use and major adverse cardiovascular events (MACE)
after coronary stent implantation.
Methods: We conducted this population-based cohort study in Western Denmark
(population: 3 million) using medical databases. We identified all 13,001 patients with
coronary stent implantation between 2002 and 2005 and their comorbidities. During
12-month follow-up, we tracked use of clopidogrel and statins and the rate of MACE.
We used Cox regression to compute hazard ratios controlling for potential confounders.
Results: The rate of MACE per 1000 person years was 104 for concomitant clopidogrel
and statin use, 129 for clopidogrel without statin use, 107 for statin without clopidogrel
use, and 449 for no use of either drug. The adjusted hazard ratio comparing clopidogrel
use with non-use was 0.68 (95% confidence interval: 0.58-0.80) among statin users
and 0.34 (95% confidence interval: 0.29-0.40) among statin non-users, yielding an
interaction effect (i.e., relative rate increase) of 1.99 (95% confidence interval: 1.61-
2.47). The adjusted hazard ratio for MACE comparing statin use with non-use was
0.97 (95% confidence interval: 0.83-1.13) among clopidogrel users and 0.49 (95%
confidence interval: 0.42-0.57) among clopidogrel non-users.
Conclusion: Clopidogrel and statin use was each associated with a substantially
reduced rate of MACE within 12 months after coronary stent implantation. Although
we observed an interaction between use of clopidogrel and statins, statin use vs. nonuse
was not associated with an increased rate of MACE in patients using clopidogrel after
coronary stent implantation.
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Background: Between 4 and 8% of pts need to undergo surgery in the first year after
DES deployment. Dual antiplatelet therapy (DAPT) is associated with a 25% incidence
of severe perioperative bleeding and is not protective against MACE, particularly in
the early months after implantation. We hypothesized that i.v. short acting perioperative
antiplatelet therapy using tirofiban during clopidogrel withdrawal would reduce the
risk of D+MI+ST with no excess in bleeding.We used a Simon two-stage design to
test the hypothesis that this approach would reduce the incidence of D+MI+ST from
30% to 5% (N=21)
Methods: Inclusion criteria:pts at high-risk for surgical bleeding within 12 months of
DES implantation.Exclusion criteria: allergy to tirofiban (tir),stroke< 30
days,intracranial disease,trombocytopenia. At day -5 to surgery (surg) stop clopidogrel.
At day -3 start tir (0,4 mg/kg/min over 30’,followed by 0,1mg/kg/min). At -4h to surg
stop tir. At +4h from surg resume tir. Resume clopidogrel as soon as oral administration
is possible. Stop tir after 1 day.ASA continued throughout.Primary EP: the composite
of death,MI,ST,haemostatic reoperation. Secondary EP: TIMI major bleeding.
Results: 56 pts enrolled in the bridge- therapy study for urgent surgery (surg) 4 days-
12 months from DES implantation (median 3 months).In 19 pts cardiovascular surg,
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